On October 31, 2025, Brii Biosciences Limited (Stock Code: 2137) announced the grant of 600,000 share options to a service provider under its 2023 Share Option Scheme. According to the announcement, the total number of issued shares as of the grant date is 720,936,585 (excluding treasury shares). Upon full exercise of the options, the new shares would account for approximately 0.08% of the issued share capital.

The service provider receiving the options offers scientific and strategic advisory services. The exercise price for each option is set at HK$1.82 per share, and the vesting schedule is divided evenly between the first and second anniversaries of the grant date, with no performance targets. The exercise period may extend up to ten years, subject to early termination provisions.

After this grant, 40,550,953 shares remain available for future grants under the 2023 Share Option Scheme’s mandate limit, while 6,681,307 shares are available under the sublimit for service providers. The board views the grant as a means to align the interests of the service provider with those of the company and its shareholders.